humLpMab-23-f(humLpMab-23-f) - 药物靶点：PDPN_在研适应症：胶质母细胞瘤，鳞状非小细胞肺癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

humLpMab 23-f

靶点

PDPN

作用机制

PDPN抑制剂(podoplanin inhibitors)

治疗领域

肿瘤神经系统疾病呼吸系统疾病+ [1]

在研适应症

胶质母细胞瘤鳞状非小细胞肺癌

非在研适应症-

原研机构

Tohoku University

在研机构

Tohoku University

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 humLpMab-23-f 相关的临床结果

登录后查看更多信息

100 项与 humLpMab-23-f 相关的转化医学

登录后查看更多信息

100 项与 humLpMab-23-f 相关的专利（医药）

登录后查看更多信息

1

项与 humLpMab-23-f 相关的文献（医药）

Cancers

A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models

Article

作者: Kaneko, Mika K. ; Suzuki, Hiroyuki ; Ohishi, Tomokazu ; Kato, Yukinari

A cancer-specific anti-PDPN mAb, LpMab-23 (mouse IgG1, kappa), was established in our previous study. We herein produced a humanized IgG1 version (humLpMab-23) and defucosylated form (humLpMab-23-f) of an anti-PDPN mAb to increase ADCC activity. humLpMab-23 recognized PDPN-overexpressed Chinese hamster ovary (CHO)-K1 (CHO/PDPN), PDPN-positive PC-10 (human lung squamous cell carcinoma), and LN319 (human glioblastoma) cells via flow cytometry. We then demonstrated that humLpMab-23-f induced ADCC and complement-dependent cytotoxicity against CHO/PDPN, PC-10, and LN319 cells in vitro and exerted high antitumor activity in mouse xenograft models, indicating that humLpMab-23-f could be useful as an antibody therapy against PDPN-positive lung squamous cell carcinomas and glioblastomas.

100 项与 humLpMab-23-f 相关的药物交易

登录后查看更多信息